Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

thekindaguyiyam 86 posts  |  Last Activity: Jun 23, 2016 1:10 AM Member since: Jun 7, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Thank you just picked up 10K at 1.64

    by makra50 Mar 28, 2016 12:54 PM
    thekindaguyiyam thekindaguyiyam Jun 23, 2016 1:10 AM Flag

    YOU are welcome. With the new Enthusiastic Afrezza Reps who are dedicated to the Afrezza the superior meal time insulin; sales will be proven and you 1.64 investment will turn into something much greater. We will prove "proof of sales" with this new team under this new management. Sanofi did their version of killing the electric car. But, it seems to me we have a resurrection. While you may have and continue to be underwater in the present; things are soon to turn around imho. If you've hung in there; I think we will be rewarded. A good thing is hard to keep repressed given that diabetes is epidemic and the population still drinks coke and eats white rice. Afrezza is only the test drug for Mannkind's Technospere which has more than 1000 patents in application to other diseases. There are hundreds of Billions at state here and Mannkind has been hit hard.
    Now... starting in July 1st. 75 Seasoned best of the 7000 applicants will enthusiastically give "appropriate education for dosing". Spirometers will be in place. 7500 Endo's targeted.... Facebook, Blogs of patients reduced A1c's will change the paradigm of dealing with more pricks than anyone ever need to have. With molecular binding of super fast in and just as fast out Afrezza kills the competition. Telsa vs. Kia. I wish that
    Alfred Mann had the view of his success. I think he had it anyway, because his vision of this was so strong.
    Pancreatic replication brought to you by Afrezza.

    And now a word from people who hate the company and hate the drug; yet have never been on the drug or know the difficulty and risk of having diabetes..... boys.. take it away.

    Sentiment: Strong Buy

  • thekindaguyiyam by thekindaguyiyam Jun 22, 2016 2:45 PM Flag

    What We’re Seeing In The Market

    It’s clear that investors are excited about the Afrezza Launch 2.0, and why wouldn’t they be. This move will likely lift sales and lead to revenue growth for MNKD. As a result, we’re seeing strong gains in the value of the stock today. Currently (10:57), the stock is trading at $1.15 per share after a gain of $0.08 per share or 7.48% thus far today.

    What We Can Expect To See Moving Forward

    Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from MannKind. The reality is that with Afrezza, the company has done something amazing for the diabetic community. After all, would you rather take your medicine through an inhaler or through a needle. The treatment is a much needed one among the pediatric community as well as the diabetic population that works in a place where public restroom access is unavailable. Now with a solid commercialization plan, I’m expecting for Afrezza to sell incredibly well. This will likely send MNKD soaring for the long run. goo glit.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 22, 2016 1:12 PM Flag

    NOT A MYTH. When discussing Diabetes on this Board with Facts presented by reliable sources: Even when Afrezza is not mentioned but the topic of Diabetes is; the regular not so intelligent posters feel that they need to block anyone who contribute FACTS about this disease. What pathetic lives they must lead. I Never read them... most of the posters are grayed out as they have nothing to offer and reflect a fear that MNKD is reversing the damage attempted by SNY. A Fact. Shorts hate Facts

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 22, 2016 12:56 PM Flag

    "Myth #4: Prediabetes is nothing to worry about.
    FACT: You either have diabetes or you don't. Doctors diagnose diabetes using several tests. Each test has cutoffs for normal, diabetes and prediabetes. Having prediabetes puts you at very high risk of developing type 2 diabetes. The good news is that you can do something about it. Research suggests that you can cut your risk by 58% if you lose 7% of your body weight and exercise moderately for 30 minutes a day, five days a week."

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 22, 2016 12:47 PM Flag

    "Myth #5: Type 2 diabetes is not as serious as type 1 diabetes.
    FACT: Left uncontrolled, both types of diabetes can cause serious complications and even be deadly. Diabetes is the 7th leading cause of death in the United States. It's also a major cause of disability. Complications include kidney disease, vision loss, neuropathy, amputations, heart attack, and stroke. Fortunately, controlling and managing type 2 diabetes can help prevent or delay these complications."

    Sentiment: Strong Buy

  • "Myth #3: Type 2 diabetes always causes symptoms.
    FACT: Symptoms of type 2 diabetes may develop slowly. In fact, the CDC (Centers for Disease Control and Prevention) estimates that about 8 million people with the disease don't even know they have it. When symptoms do develop, people may not recognize them right away because they are mild or vague. The telltale symptoms of type 2 diabetes are increased urination, thirst and hunger. Other symptoms include weight loss and fatigue; slow-healing wounds and blurred vision typically occur later in the disease."

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 22, 2016 11:10 AM Flag

    As I maintain; Yahoo is Not a friend of MNKD. It serves short interest as a FUD tool. Yahoo reprinted the collaboration statement on June 9, 2016. They should know better; but from all we know it was done by a bot.
    No relevance here. Sanofi is out of the picture except for the financial settle up.

    Sentiment: Strong Buy

  • thekindaguyiyam by thekindaguyiyam Jun 20, 2016 6:23 PM Flag

    With overwhelming negative articles from these guys they finally post another positive story.
    "Summary: 1. Better data = better presentations to physicians and patients., 2. A dedicated, focused, and targeted sales force. 3. CEO and company are 100% focused on the success of Afrezza."

    Sentiment: Strong Buy

  • Reply to

    To get out?

    by smithmanmodel10 Jun 15, 2016 11:05 AM
    thekindaguyiyam thekindaguyiyam Jun 16, 2016 3:49 PM Flag

    use your finder to discover new news within the last 24 hours. Articles pop up that yahoo won't allow to be represented in this message room application. I must have included some words in the last one that auto-delete. And if you hear anyone say that they made contact with Yahoo who told the poster that there were so many posts from an IP address... that poster is a liar. You might as well try to get to a human being at phillip morris. There are no human being overviewing these posts. The violation button does nothing other than giving people a way to vent... it has Nothing to do with removing posts. Consider flash trading... here at Yahoo it's flash messaging to get rid of those comments about Afrezza that are bullish.

    Sentiment: Strong Buy

  • thekindaguyiyam by thekindaguyiyam Jun 16, 2016 3:44 PM Flag

    CNAarticle 1/16/16 within the last 4 hours. Yahoo deleted this post. Here it is again; though I imagine it will disappear too.

    Sentiment: Strong Buy

  • Reply to

    Fragsuck and longs!

    by melbrad77 Jun 15, 2016 2:34 PM
    thekindaguyiyam thekindaguyiyam Jun 15, 2016 2:45 PM Flag

    walk the talk; You are the one who just brought him up. Those who focus on noise do as much damage as the noise makers. Today you are one of them. IGNORE Button is there for a reason.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 12, 2016 3:17 PM Flag

    and this is what we are going to see; one affirmation after another. Good Post. Thanks!

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 12, 2016 12:48 PM Flag

    another prediction without factual reference as useful as a bag full of hammers.
    I'm Long. Creating expectations based on nothing is just a circus act. Give us facts. Give us references.

    Sentiment: Strong Buy

  • thekindaguyiyam by thekindaguyiyam Jun 2, 2016 2:49 PM Flag

    "Why there’s been a dangerous diabetes spike around the globe" Title of article

    google it.
    Diabetes is becoming epidemic.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 1, 2016 4:03 PM Flag

    I respectfully disagree with you. The report abuse does nothing. There are no humans involved. I've been on some boards where one poster was hated; dozens of abuse complaints were made and nothing happened to his posts.

    The post I'm speaking of still exists. The one liners... and first timers with multiple aliases roll back the important posts and can do so very quickly. Yahoo is NOT a good guy in terms of how it's boards are used by short interest.

    Sentiment: Strong Buy

  • Reply to

    Afrezza sales rep

    by user5005 May 29, 2016 4:17 PM
    thekindaguyiyam thekindaguyiyam Jun 1, 2016 3:49 PM Flag

    look up the name of the poster A Yahoo! User what a clown. I put you on my ignore list but you keep showing up and when I look up how many posts you've made and when you established your ID what I get is an Error message. You are that Error.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 1, 2016 3:44 PM Flag

    "Consequently, despite the concerns raised by others who may be used to a more traditional model for marketing pharmaceuticals, I do not believe it is at all far-fetched to think that Afrezza really could end up “selling itself” for MannKind… especially if the skids have been sufficiently greased ahead of time by MannKind for patients to advocate for themselves at the doctor’s office (again, “educational awareness” is something that I am convinced did not happen under Sanofi’s watch… but will under MannKind’s).

    That being said, as anyone who has diabetes (or knows someone who does) can tell you, whether it is injected or inhaled, “dialing in” insulin is as much an art as it is a science.

    And, along these lines, as more information has been gathered from the field, it appears that the approach Sanofi took in trying to get patients to switch involved very little (if any) training on how to capture the benefits offered by Afrezza. Consequently, I think the plan that has been laid out by the company (and headed up by Mike Castagna, a guy who I think we are going to be hearing a lot more from – and about – in the years ahead!) has the potential to make some significant changes to the prescription trajectory in a fairly short period of time.

    Sentiment: Strong Buy

  • thekindaguyiyam thekindaguyiyam Jun 1, 2016 3:04 PM Flag

    from Forbes today 6/1/16

    Ken Kam: What does the market expect from the company?

    Nate Pile: As you can see from the current stock price, what the market is currently expecting is that the company will never sell more Afrezza than Sanofi was able to… and, therefore, “it is on a path to bankruptcy.”

    Kam: What is the market missing?

    Pile: What I believe the market is missing is that Afrezza isn’t just an inhalable version of the same prandial (mealtime) insulin that is currently on the market; rather, Afrezza has a significantly different “activity profile” than traditional mealtime insulins due to the fact that not only is it inhaled rather than injected, but perhaps more importantly, due to the fact that it is monomeric rather than hexameric in nature… and, therefore, it is essentially “ready to get to work” as soon as it hits bloodstream.

    This “faster in and faster out” profile offers many significant advantages over existing mealtime insulins, with the two most notable being that anyone using a continuous glucose monitor to watch their blood sugar levels in real time (a situation that is becoming more and more common as the technology becomes cheaper and less obtrusive) now has an insulin available to them that can also address rising blood sugar levels in real time, and
    since Afrezza leaves the blood stream much more quickly than traditional mealtime insulins, it is less likely to cause hypoglycemia (which is a far more serious problem for diabetics to contend with than high blood sugar levels). .... continues

    Sentiment: Strong Buy

  • AFREZZA SALES REP by user5005 • May 29, 2016 4:17 PM
    8 users liked this post
    15 disliked this post

    try to find it. once this phony got discredited ... the post wasn't erased it was processed out of sight.
    This is a part of the illusion ... they don't want us to see their failed attempts when caught lying.

    Sentiment: Strong Buy

  • Reply to

    Afrezza sales rep

    by user5005 May 29, 2016 4:17 PM
    thekindaguyiyam thekindaguyiyam Jun 1, 2016 2:13 PM Flag

    1) you are selling medicine to Physicians to show superiority.
    2) who do you think a good source of information would be "investors" in stock / which are both longs & shorts
    3) who might be the better source of info... those who teach you how to talk to doctors... some of whom might be actual Afrezza Patients.

    You are Not a MNKD representative. You are nobody.

    user5005
    9 posts | Last Activity: May 30, 2016 8:34 PM
    Member since: May 29, 2016

MNKD
1.17-0.08(-6.40%)Jun 27 4:00 PMEDT